Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced
“This positive safety review marks an important milestone in the development of our allogeneic gamma delta platform, building on the strong safety profile that we previously established for our novel therapeutic,” said Bryan Kobel, Chief Executive Officer of TC BioPharm. “We expect the trial to enroll well in 2024, as we believe there is a high degree of interest in our therapeutic and a growing recognition of the role gamma deltas play in the fight against cancer. We will begin redosing in ACHIEVE based on the compelling existing therapeutic profile. While the process has been relatively slow getting to this point in ACHIEVE, we believe those headwinds to have subsided and been addressed by our team and we look forward to a more rapid open enrollment throughout 2024 now that the safety portion of the trial is complete.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome